Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia

MB Pappalardi, K Keenan, M Cockerill, WA Kellner… - Nature cancer, 2021 - nature.com
DNA methylation, a key epigenetic driver of transcriptional silencing, is universally
dysregulated in cancer. Reversal of DNA methylation by hypomethylating agents, such as …
被引用次数：122 相关文章

Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia

MB Pappalardi, K Keenan, M Cockerill… - Nature …, 2021 - mdanderson.elsevierpure.com
DNA methylation, a key epigenetic driver of transcriptional silencing, is universally
dysregulated in cancer. Reversal of DNA methylation by hypomethylating agents, such as …

Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia

MB Pappalardi, K Keenan, M Cockerill… - Nature …, 2021 - pubmed.ncbi.nlm.nih.gov
DNA methylation, a key epigenetic driver of transcriptional silencing, is universally
dysregulated in cancer. Reversal of DNA methylation by hypomethylating agents, such as …

Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia

MB Pappalardi, K Keenan, M Cockerill… - Nature …, 2021 - pure.johnshopkins.edu
DNA methylation, a key epigenetic driver of transcriptional silencing, is universally
dysregulated in cancer. Reversal of DNA methylation by hypomethylating agents, such as …

[引用][C] Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia

MB Pappalardi, K Keenan, M Cockerill, WA Kellner… - 2021 - christie.openrepository.com
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and
efficacy in acute myeloid leukemia Toggle navigation Login Toggle navigation View Item Home …

[引用][C] Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia

MB Pappalardi, K Keenan, M Cockerill, WA Kellner… - Nature Cancer, 2021 - cir.nii.ac.jp
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and
efficacy in acute myeloid leukemia | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …

Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia.

MB Pappalardi, K Keenan, M Cockerill, WA Kellner… - Nature Cancer, 2021 - europepmc.org
DNA methylation, a key epigenetic driver of transcriptional silencing, is universally
dysregulated in cancer. Reversal of DNA methylation by hypomethylating agents, such as …
[HTML] nih.gov

[HTML][HTML] Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia

MB Pappalardi, K Keenan, M Cockerill, WA Kellner… - Nature …, 2021 - ncbi.nlm.nih.gov
DNA methylation, a key epigenetic driver of transcriptional silencing, is universally
dysregulated in cancer. Reversal of DNA methylation by hypomethylating agents, such as …